State coverage
Medicaid, for obesity: Does not cover. Coverage for weight loss ended January 1, 2026. GLP-1s stay covered for other approved uses.
California stopped paying for GLP-1 drugs used for weight loss on January 1, 2026. The change came out of the 2025-26 state budget, and the state gave a long warning: a countdown alert in October, a second notice three weeks later, a letter mailed to members, and an expiry date on every prior authorization already granted.
That is not the same as the drugs leaving Medi-Cal. The state kept covering them for other uses the FDA has approved, and it still pays for two of the newer weight-management products for narrow reasons that are not weight loss. What ended is weight loss as a reason for Medi-Cal to pay.
One thing makes California simpler to read than most states: the pharmacy benefit runs statewide through Medi-Cal Rx rather than through whichever managed care plan you belong to, and the state's own member letter says the change applies to every Medi-Cal member. Elsewhere on this site you will see us warn that a state posture may not describe your plan. Here, the state said it does.
Medi-Cal Rx's provider manual lists GLP-1 drugs used for chronic weight management as an item it does not cover. The manual's words are "Glucagon-like peptide-1 (GLP-1) drugs used for chronic weight management or weight loss-related indications," with an exception "when GLP-1 drugs are used for other FDA-approved indications or for considerations under the EPSDT benefit."
California Department of Health Care Services, Medi-Cal Rx, effective August 2026 · source · read August 2026
Zepbound and Saxenda came off the Contract Drugs List on January 1, 2026 and claims for them now deny regardless of what they were prescribed for. Wegovy stopped being eligible for weight loss on the same date. The state will still consider Zepbound for obstructive sleep apnea, and since April 1, 2026 Wegovy needs no prior authorization at all when it is prescribed for MASH.
California Department of Health Care Services, Medi-Cal Rx, effective April 2026 · source · read August 2026
Seven other GLP-1 drugs — Ozempic, Rybelsus, Mounjaro, Victoza, Byetta, Bydureon and Trulicity — are still on the Contract Drugs List, still carry a type 2 diabetes diagnosis restriction, and stopped being eligible for weight loss on January 1, 2026. There is one exception the state names: for members younger than 21, a request for a weight-loss indication is still reviewed for medical necessity under the federal EPSDT benefit.
California Department of Health Care Services, Medi-Cal Rx, effective April 2026 · source · read August 2026
The bulletin that announced it is dated October 21, 2025 and names the three drugs dropped for weight loss: Saxenda, Wegovy and Zepbound. It also tells you what a pharmacy sees at the counter — Reject Code 70, Product/Service Not Covered — and that every prior authorization already approved for those drugs expired on December 31, 2025. The document now carries an ARCHIVED watermark, which is what happens to an announcement after its date passes; the policy it announced is the one in force.
California Department of Health Care Services, Medi-Cal Rx, effective January 2026 · source · read August 2026
The letter California mailed to members carries the appeal route. It says members generally have 90 days from the date of the Notice of Action to ask the Department of Social Services in writing for a State Hearing. It also says something easy to miss: a member already taking a GLP-1 who asks for a State Hearing within 10 days of that notice may keep receiving the drug while the hearing is decided.
California Department of Health Care Services, Medi-Cal Rx, effective November 2025 · source · read August 2026
The same letter settles the question of who this applies to, in four words: "This change is for all Medi-Cal members." California administers the pharmacy benefit statewide through Medi-Cal Rx, so unlike most states there is no separate managed care drug list that could answer differently.
California Department of Health Care Services, Medi-Cal Rx, effective November 2025 · source · read August 2026
Medicaid is only one of the routes. If you have a commercial or employer plan, the rules are different and are on the employer plans page; Medicare has a federal rule of its own, on the Part D page.
If the appeal fails, or you cannot wait
Cash-pay telehealth is the fallback, not the bargain: you pay the whole cost yourself, and a covered prescription is almost always cheaper than any of these. Use this route when coverage has actually been exhausted, or when you need to start while an appeal runs.
These companies pay us a commission if you start care through the links below. That is how this site is funded, and it does not change what is written above. How we pay for this.
Prices in those notes were read from each company's own site in August 2026 and change often. Check the current number before you buy.
Every state we have verified is in the coverage matrix. Appeal routes and deadlines are on the procedures page.